A Regeneron Pharmaceuticals Inc. antibody cocktail may help treat coronavirus patients outside of the hospital by reducing virus levels and symptoms, early study results indicate.
In an early-stage clinical trial of 275 Covid-19 patients, those who received Regeneron’s experimental therapy had lower virus levels in the bloodstream seven days later compared with patients who received a placebo, the company said in a statement.
